Reuters logo
4 个月前
BRIEF-Pfizer’s ALK/ROS1 inhibitor granted breakthrough therapy designation from FDA
2017年4月27日 / 中午12点19分 / 4 个月前

BRIEF-Pfizer’s ALK/ROS1 inhibitor granted breakthrough therapy designation from FDA

April 27 (Reuters) - Pfizer Inc

* pfizer’s next-generation alk/ros1 inhibitor, lorlatinib, granted breakthrough therapy designation from fda for alk-positive metastatic non-small cell lung cancer

* Pfizer inc says additionally, phase 3 crown study (nct03052608) recently began enrolling patients Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below